(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
2 days till quarter result
(bmo 2024-05-06)
Expected move: +/- 13.17%
@ $16.24
Utstedt: 2 mai 2024 @ 20:38
Avkastning: -0.31%
Forrige signal: mai 2 - 19:08
Forrige signal:
Avkastning: 0.68 %
Live Chart Being Loaded With Signals
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases...
Stats | |
---|---|
Dagens volum | 4.77M |
Gjennomsnittsvolum | 3.81M |
Markedsverdi | 2.50B |
EPS | $0 ( 2024-04-29 ) |
Neste inntjeningsdato | ( $-0.0360 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 179.89 |
ATR14 | $0.989 (6.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Lonial Sagar | Sell | 5 000 | Common Stock |
2024-03-12 | Charney Laurence N | Sell | 22 000 | Common Stock |
2024-02-14 | Power Sean A | Buy | 0 | |
2024-01-05 | Charney Laurence N | Sell | 17 500 | Common Stock |
2024-01-06 | Weiss Michael S | Buy | 1 001 908 | Common Stock |
INSIDER POWER |
---|
83.47 |
Last 94 transactions |
Buy: 12 977 390 | Sell: 1 920 924 |
Volum Korrelasjon
TG Therapeutics Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
LWAC | 0.972 |
PUCK | 0.963 |
SCAQ | 0.956 |
NVCN | 0.954 |
ALSA | 0.952 |
KALV | 0.952 |
HERAU | 0.951 |
TWLV | 0.951 |
SY | 0.951 |
NVSA | 0.951 |
10 Mest negative korrelasjoner | |
---|---|
AMGN | -0.942 |
NAKD | -0.939 |
STAB | -0.936 |
TUEM | -0.935 |
LGMK | -0.934 |
PROC | -0.933 |
ORPH | -0.932 |
AHPI | -0.931 |
PCSA | -0.928 |
DBGI | -0.92 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
TG Therapeutics Inc Korrelasjon - Valuta/Råvare
TG Therapeutics Inc Økonomi
Annual | 2023 |
Omsetning: | $233.66M |
Bruttogevinst: | $219.11M (93.77 %) |
EPS: | $0.0893 |
FY | 2023 |
Omsetning: | $233.66M |
Bruttogevinst: | $219.11M (93.77 %) |
EPS: | $0.0893 |
FY | 2022 |
Omsetning: | $2.79M |
Bruttogevinst: | $2.52M (90.48 %) |
EPS: | $-1.510 |
FY | 2021 |
Omsetning: | $6.69M |
Bruttogevinst: | $5.90M (88.19 %) |
EPS: | $-2.63 |
Financial Reports:
No articles found.
TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.